Pub Date : 2025-11-26eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3608
Gerson D Keppeke, Diana Landoni, Cristiane Kayser, Pedro Matos, Larissa Diogenes, Jessica Keppeke, Silvia Helena Rodrigues, Luis Eduardo C Andrade
Introduction: Anti-centromere antibodies are associated with limited cutaneous systemic sclerosis (lcSSc) and a more favorable prognosis. The centromere HEp-2 pattern (AC-3) suggests the presence of antibodies against CENP antigens, mainly CENP-B/A. This study analyzed clinical and demographic associations of anti-centromere antibodies in a cohort of patients exclusively with the lcSSc form of SSc. The frequency of CENP-B and CENP-A reactivity in samples with the AC-3 pattern was also evaluated.
Method: Samples from 38 lcSSc patients with AC-3 were evaluated for reactivity to CENP-B/A using line-blot and ELISA. Clinical data from 68 lcSSc patients (20 AC-3 and 48 Non-AC-3) were analyzed.
Results: Of the AC-3 samples, 84% and 82% were reactive against CENP-B and CENP-A, respectively, by line-blot, and 92% were positive for CENP-B by ELISA. Concordance for CENP-B reactivity between ELISA and line-blot was 79%. Reactivity to both CENP-B and CENP-A was found in 68% of AC-3 samples, while one sample was positive only for CENP-A. Overall, 97% of AC-3 samples were reactive to CENP-B, and all were reactive to either CENP-B or CENP-A. Clinically, interstitial lung disease (ILD) was less frequent in AC-3 patients compared to Non-AC-3 (10.5% vs. 54.2%; p = 0.001). Other organ involvement frequencies were similar.
Conclusion: ILD was less frequent in lcSSc patients with a positive AC-3 pattern as compared to those with a non-AC-3 pattern, which could suggest a less severe prognosis. In addition, anti-CENP-B was the predominant autoantibody in samples yielding the AC-3 pattern, but anti-CENP-A reactivity was also prevalent, and exclusive anti-CENP-A reactivity was also observed.
抗着丝粒抗体与局限性皮肤系统性硬化症(lcSSc)和更有利的预后有关。着丝粒HEp-2模式(AC-3)提示存在针对CENP抗原的抗体,主要是CENP- b /A。本研究分析了lcSSc型SSc患者队列中抗着丝粒抗体的临床和人口统计学关联。还对具有AC-3模式的样品中CENP-B和CENP-A的反应频率进行了评估。方法:采用line-blot和ELISA检测38例AC-3 lcSSc患者对CENP-B/A的反应性。对68例lcSSc患者(20例AC-3, 48例非AC-3)的临床资料进行分析。结果:AC-3细胞系对CENP-B和CENP-A的阳性检出率分别为84%和82%,ELISA对CENP-B的阳性检出率为92%。ELISA和line-blot对CENP-B反应性的一致性为79%。68%的AC-3样品对CENP-B和CENP-A均有反应,而一个样品仅对CENP-A呈阳性。总的来说,97%的AC-3样本对CENP-B有反应,所有的AC-3样本对CENP-B或CENP-A都有反应。在临床上,AC-3患者的间质性肺病(ILD)发生率低于非AC-3患者(10.5% vs. 54.2%; p = 0.001)。其他器官受累频率相似。结论:与非AC-3型的lcSSc患者相比,AC-3型阳性的lcSSc患者的ILD发生率较低,这可能表明预后较轻。此外,在产生AC-3模式的样品中,抗cenp - b是主要的自身抗体,但抗cenp - a反应性也普遍存在,并且还观察到特异性的抗cenp - a反应性。
{"title":"Anti-CENP-A/B reactivity in samples exhibiting the centromere HEp-2 pattern is associated with a lower frequency of interstitial lung disease in limited cutaneous systemic sclerosis patients.","authors":"Gerson D Keppeke, Diana Landoni, Cristiane Kayser, Pedro Matos, Larissa Diogenes, Jessica Keppeke, Silvia Helena Rodrigues, Luis Eduardo C Andrade","doi":"10.33393/jcb.2025.3608","DOIUrl":"https://doi.org/10.33393/jcb.2025.3608","url":null,"abstract":"<p><strong>Introduction: </strong>Anti-centromere antibodies are associated with limited cutaneous systemic sclerosis (lcSSc) and a more favorable prognosis. The centromere HEp-2 pattern (AC-3) suggests the presence of antibodies against CENP antigens, mainly CENP-B/A. This study analyzed clinical and demographic associations of anti-centromere antibodies in a cohort of patients exclusively with the lcSSc form of SSc. The frequency of CENP-B and CENP-A reactivity in samples with the AC-3 pattern was also evaluated.</p><p><strong>Method: </strong>Samples from 38 lcSSc patients with AC-3 were evaluated for reactivity to CENP-B/A using line-blot and ELISA. Clinical data from 68 lcSSc patients (20 AC-3 and 48 Non-AC-3) were analyzed.</p><p><strong>Results: </strong>Of the AC-3 samples, 84% and 82% were reactive against CENP-B and CENP-A, respectively, by line-blot, and 92% were positive for CENP-B by ELISA. Concordance for CENP-B reactivity between ELISA and line-blot was 79%. Reactivity to both CENP-B and CENP-A was found in 68% of AC-3 samples, while one sample was positive only for CENP-A. Overall, 97% of AC-3 samples were reactive to CENP-B, and all were reactive to either CENP-B or CENP-A. Clinically, interstitial lung disease (ILD) was less frequent in AC-3 patients compared to Non-AC-3 (10.5% vs. 54.2%; p = 0.001). Other organ involvement frequencies were similar.</p><p><strong>Conclusion: </strong>ILD was less frequent in lcSSc patients with a positive AC-3 pattern as compared to those with a non-AC-3 pattern, which could suggest a less severe prognosis. In addition, anti-CENP-B was the predominant autoantibody in samples yielding the AC-3 pattern, but anti-CENP-A reactivity was also prevalent, and exclusive anti-CENP-A reactivity was also observed.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"54-63"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12651629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145639405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) may be considered an effective option in the neoadjuvant setting for metastatic colon cancer (mCRC). To investigate potential molecular criteria for treatment response, we evaluate the transcriptome of paired primary colon tumors and liver metastases.
Method: Two sets of quadruple-matched specimens (primary colon tumor, liver metastasis, normal colon and liver tissues) from five patients with resectable mCRC before and after neoadjuvant FOLFOXIRI were selected for RNA sequencing (RNA-seq).
Results: RNA-seq data showed that liver metastases exhibited a higher number of differentially expressed genes (DEGs) than colon tumors (FDR < 0.05, 301 vs. 62, respectively). Up-regulation of IL1RN, MTCO1P12, RN7SL1, ALDH1A1, DUSP1, COX1, and FOS may be associated with colon tumor sensitivity to FOLFOXIRI. HBB, GADD45B, DUSP1, FOSB, HBA2, TSC22D3, TAGLN, PER1, CSRP1, CCN2, NAMPT, ZBTB16, SERPINE1, ISG20, SRGN, ATF3, IL7R, IFITM2, and KLF2 may potentially be involved in the partial liver metastasis response. EPS8L2 was the only gene highly expressed in pre-treatment liver tissue of the complete responder patient compared to others (|Log2FC| = 3.84, FDR < 0.05).
Conclusion: Data obtained indicate transcriptional discordance between the primary tumors and liver metastases during neoadjuvant FOLFOXIRI, with the pattern of DEGs involved in their response being distinct. The EPS8L2 transcript could be regarded as a candidate biomarker of liver complete response; however, prognostic conclusions cannot be drawn from this cohort.
{"title":"Transcriptome biomarkers of colon cancer liver metastasis response to neoadjuvant triplet chemotherapy: a case series.","authors":"Nataliya Babyshkina, Tatyana Dronova, Dmitry Eremin, Alexey Dobrodeev, Dmitry Kostromitskiy, Sergey Vtorushin, Polina Gervas, Sergey Afanasiev, Nadejda Cherdyntseva","doi":"10.33393/jcb.2025.3597","DOIUrl":"10.33393/jcb.2025.3597","url":null,"abstract":"<p><strong>Introduction: </strong>The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) may be considered an effective option in the neoadjuvant setting for metastatic colon cancer (mCRC). To investigate potential molecular criteria for treatment response, we evaluate the transcriptome of paired primary colon tumors and liver metastases.</p><p><strong>Method: </strong>Two sets of quadruple-matched specimens (primary colon tumor, liver metastasis, normal colon and liver tissues) from five patients with resectable mCRC before and after neoadjuvant FOLFOXIRI were selected for RNA sequencing (RNA-seq).</p><p><strong>Results: </strong>RNA-seq data showed that liver metastases exhibited a higher number of differentially expressed genes (DEGs) than colon tumors (FDR < 0.05, 301 vs. 62, respectively). Up-regulation of <i>IL1RN, MTCO1P12, RN7SL1, ALDH1A1, DUSP1, COX1</i>, and <i>FOS</i> may be associated with colon tumor sensitivity to FOLFOXIRI. <i>HBB, GADD45B, DUSP1, FOSB, HBA2, TSC22D3, TAGLN, PER1, CSRP1, CCN2, NAMPT, ZBTB16, SERPINE1, ISG20, SRGN, ATF3, IL7R, IFITM2</i>, and <i>KLF2</i> may potentially be involved in the partial liver metastasis response. <i>EPS8L2</i> was the only gene highly expressed in pre-treatment liver tissue of the complete responder patient compared to others (|Log2FC| = 3.84, FDR < 0.05).</p><p><strong>Conclusion: </strong>Data obtained indicate transcriptional discordance between the primary tumors and liver metastases during neoadjuvant FOLFOXIRI, with the pattern of DEGs involved in their response being distinct. The EPS8L2 transcript could be regarded as a candidate biomarker of liver complete response; however, prognostic conclusions cannot be drawn from this cohort.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"48-53"},"PeriodicalIF":0.0,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12603631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-10eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3657
Diksha Singh, Prashant P Rokade, Neeraj K Gangwar, Mukul G Gabhane, Sunil Malik, Kavisha Gangwar, Shyama N Prabhu, Renu Singh, D D Singh, Sonam Kumari, Soumen Chaudhary, Jitendra K Choudhary
[This corrects the article DOI: 10.33393/jcb.2025.3564.].
[这更正了文章DOI: 10.33393/jcb.2025.3564.]。
{"title":"Erratum in \"Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor\".","authors":"Diksha Singh, Prashant P Rokade, Neeraj K Gangwar, Mukul G Gabhane, Sunil Malik, Kavisha Gangwar, Shyama N Prabhu, Renu Singh, D D Singh, Sonam Kumari, Soumen Chaudhary, Jitendra K Choudhary","doi":"10.33393/jcb.2025.3657","DOIUrl":"10.33393/jcb.2025.3657","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.33393/jcb.2025.3564.].</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"46-47"},"PeriodicalIF":0.0,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12513370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145281234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-07eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3561
Muslima Mahmood Ismail, Abdulhakeem D Hussein, Othman Ghazi Najeeb, Mohammed Hadi Ali Al-Jumaili
Introduction: The coronavirus is a novel pandemic disease that began in Wuhan, China, and further spread globally. Therefore, the aim of this retrospective work was to look at the clinical characteristics and outcomes of diabetic and blood pressure patients compared with a healthy patient who was infected with coronavirus disease (COVID-19).
Methods: Data and outcomes were gathered from medical records and analyzed in 150 patients. The disease is frequently diagnosed via nucleic acid-based viral identification from swabs, sputum, or bronchial alveolar lavage fluid (BALF) using diagnostic reagents such as quantitative reverse transcription-polymerase chain reaction (RT-qPCR). COVID-19 chest radiographs were obtained, and clinical characteristics and outcomes were evaluated. In this study, we analyzed and compared the severity of the disease, its outcome, any associated complications, and clinical laboratory findings in COVID-19 patients between diabetic, hypertensive, and healthy individuals.
Results and conclusion: According to the findings, COVID-19 can cause a wide range of symptoms, which range from asymptomatic to severe respiratory problems and death. Diabetes appears to be one of the most significant comorbidities associated with a worse COVID-19 result. COVID-19 patients with diabetes (50 (33%) and hypertension (50 (33%)) had more ICU admissions compared with the non-diabetic and non-blood pressure patients (50 (33%)). During the treatment follow-up, 10 (6.6%) of the 150 patients passed away, 140 (93%) were released, 110 (73%) were discharged, and 30 (20%) kept in the hospital. Compared to non-diabetic and healthy COVID-19 patients, diabetic COVID-19 patients had a greater mortality rate.
{"title":"Association of hypertension and diabetes with COVID-19 severity in comparison to healthy patients.","authors":"Muslima Mahmood Ismail, Abdulhakeem D Hussein, Othman Ghazi Najeeb, Mohammed Hadi Ali Al-Jumaili","doi":"10.33393/jcb.2025.3561","DOIUrl":"10.33393/jcb.2025.3561","url":null,"abstract":"<p><strong>Introduction: </strong>The coronavirus is a novel pandemic disease that began in Wuhan, China, and further spread globally. Therefore, the aim of this retrospective work was to look at the clinical characteristics and outcomes of diabetic and blood pressure patients compared with a healthy patient who was infected with coronavirus disease (COVID-19).</p><p><strong>Methods: </strong>Data and outcomes were gathered from medical records and analyzed in 150 patients. The disease is frequently diagnosed via nucleic acid-based viral identification from swabs, sputum, or bronchial alveolar lavage fluid (BALF) using diagnostic reagents such as quantitative reverse transcription-polymerase chain reaction (RT-qPCR). COVID-19 chest radiographs were obtained, and clinical characteristics and outcomes were evaluated. In this study, we analyzed and compared the severity of the disease, its outcome, any associated complications, and clinical laboratory findings in COVID-19 patients between diabetic, hypertensive, and healthy individuals.</p><p><strong>Results and conclusion: </strong>According to the findings, COVID-19 can cause a wide range of symptoms, which range from asymptomatic to severe respiratory problems and death. Diabetes appears to be one of the most significant comorbidities associated with a worse COVID-19 result. COVID-19 patients with diabetes (50 (33%) and hypertension (50 (33%)) had more ICU admissions compared with the non-diabetic and non-blood pressure patients (50 (33%)). During the treatment follow-up, 10 (6.6%) of the 150 patients passed away, 140 (93%) were released, 110 (73%) were discharged, and 30 (20%) kept in the hospital. Compared to non-diabetic and healthy COVID-19 patients, diabetic COVID-19 patients had a greater mortality rate.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"39-45"},"PeriodicalIF":0.0,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-21eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3564
Diksha Singh, Prashant P Rokade, Neeraj K Gangwar, Mukul G Gabhane, Sunil Malik, Kavisha Gangwar, Shyama N Prabhu, Renu Singh, D D Singh, Sonam Kumari, Soumen Chaudhary, Jitendra K Choudhary
Introduction: Blood biomarkers play a crucial role in the diagnosis and prognosis of tumor. The present research was designed to study the diagnostic effect of serum biomarkers, namely carcino-embryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and plasma biomarker viz., circulating cell-free DNA (cfDNA); and their correlation with cytological and histopathological results.
Methods: A total of 60 blood samples were collected. Out of which 36 samples were from the dogs affected with canine mammary tumors, and 24 samples were from the apparently healthy dogs. CEA and CA15-3 were estimated using Sandwich ELISA, and cfDNA was estimated by the ccfDNA kit. A significant Positive correlation was observed between tumor blood biomarker levels, cytology and histopathological grades of the tumors.
Results: We found that CA15-3 can be a more effective serum tumour biomarker than CEA for diagnosing canine mammary gland tumours. This finding showed a positive correlation with the clinical grade of the disease. The concentration of serum markers and cfDNA in animals affected with malignant mammary gland tumours was higher compared to the benign entity of tumours and healthy control groups. The ROC curve analysis revealed that the sensitivity (Se) and specificity (Sp) of CEA and CA15-3 biomarkers improved when used together. IN comparison to healthy controls, canines with both benign and malignant neoplasia showed significantly higher (p < 0.05) cfDNA concentrations.
Conclusion: This study highlights the role of blood tumor biomarkers for routine screening of animals in early diagnosis of tumors, further treatment, and prognosis.
{"title":"Diagnostic value of carcinoembryonic antigen, cancer antigen 15-3, and cell-free DNA as blood biomarkers in early detection of canine mammary tumor.","authors":"Diksha Singh, Prashant P Rokade, Neeraj K Gangwar, Mukul G Gabhane, Sunil Malik, Kavisha Gangwar, Shyama N Prabhu, Renu Singh, D D Singh, Sonam Kumari, Soumen Chaudhary, Jitendra K Choudhary","doi":"10.33393/jcb.2025.3564","DOIUrl":"10.33393/jcb.2025.3564","url":null,"abstract":"<p><strong>Introduction: </strong>Blood biomarkers play a crucial role in the diagnosis and prognosis of tumor. The present research was designed to study the diagnostic effect of serum biomarkers, namely carcino-embryonic antigen (CEA), cancer antigen 15-3 (CA15-3), and plasma biomarker <i>viz.,</i> circulating cell-free DNA (cfDNA); and their correlation with cytological and histopathological results.</p><p><strong>Methods: </strong>A total of 60 blood samples were collected. Out of which 36 samples were from the dogs affected with canine mammary tumors, and 24 samples were from the apparently healthy dogs. CEA and CA15-3 were estimated using Sandwich ELISA, and cfDNA was estimated by the ccfDNA kit. A significant Positive correlation was observed between tumor blood biomarker levels, cytology and histopathological grades of the tumors.</p><p><strong>Results: </strong>We found that CA15-3 can be a more effective serum tumour biomarker than CEA for diagnosing canine mammary gland tumours. This finding showed a positive correlation with the clinical grade of the disease. The concentration of serum markers and cfDNA in animals affected with malignant mammary gland tumours was higher compared to the benign entity of tumours and healthy control groups. The ROC curve analysis revealed that the sensitivity (Se) and specificity (Sp) of CEA and CA15-3 biomarkers improved when used together. IN comparison to healthy controls, canines with both benign and malignant neoplasia showed significantly higher (p < 0.05) cfDNA concentrations.</p><p><strong>Conclusion: </strong>This study highlights the role of blood tumor biomarkers for routine screening of animals in early diagnosis of tumors, further treatment, and prognosis.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"30-38"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12375963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Sepsis is a life-threatening condition and a major cause of hospital mortality worldwide. This study investigated the diagnostic utility of monocyte mean volume (MONO MEAN-V), monocyte distribution width (MDW), monocyte mean conductivity (MONO MEAN-C), and monocyte standard deviation conductivity (MONO Sd-C) for sepsis, compared to conventional markers.
Methods: A prospective cohort study was conducted in two centers, enrolling adult patients classified into three groups: sepsis, septic shock, and febrile. Blood was drawn from septic patients on days 1, 3, and 5 of admission. MDW and other inflammatory parameters were measured in all patients.
Results: Patients with sepsis or septic shock exhibited significantly elevated MONO MEAN-V, MDW, and MONO MEAN-C and lower MONO Sd-C compared to febrile patients. Among the biomarkers evaluated, MDW emerged as a reliable predictor of sepsis. A cut-off MDW value of 25.1 on day 1 demonstrated optimal diagnostic performance, with an area under the ROC curve of 0.84 (95% CI: 0.77-0.91), sensitivity of 75%, and specificity of 91.2%.
Conclusions: MDW appears to be a cost-effective, rapid marker for sepsis detection, performing at least as effectively as existing biomarkers. Our findings corroborate other published studies, highlighting MDW's potential to enhance early sepsis recognition.
背景:脓毒症是一种危及生命的疾病,也是世界范围内医院死亡的主要原因。本研究探讨了单核细胞平均体积(MONO mean - v)、单核细胞分布宽度(MDW)、单核细胞平均电导率(MONO mean - c)和单核细胞标准偏差电导率(MONO Sd-C)对败血症的诊断价值,并与传统标志物进行了比较。方法:在两个中心进行前瞻性队列研究,将成年患者分为三组:败血症、感染性休克和发热。脓毒症患者于入院第1、3、5天抽血。所有患者均测量MDW及其他炎症参数。结果:与发热患者相比,脓毒症或感染性休克患者表现出明显升高的MONO MEAN-V、MDW和MONO MEAN-C,以及较低的MONO Sd-C。在评估的生物标志物中,MDW成为脓毒症的可靠预测指标。第1天的MDW截值为25.1,ROC曲线下面积为0.84 (95% CI: 0.77-0.91),敏感性为75%,特异性为91.2%。结论:MDW似乎是一种具有成本效益的、快速的败血症检测标志物,至少与现有的生物标志物一样有效。我们的发现证实了其他已发表的研究,强调了MDW增强早期败血症识别的潜力。
{"title":"Monocyte Distribution Width (MDW) as a useful and cost-effective biomarker for sepsis prediction.","authors":"Dimitrios Theodoridis, Angeliki Tsifi, Emmanouil Magiorkinis, Riris Ioannis, Vatistas Ioannis, Evgenia Moustaferi, Kanakaris Christos, Tsiligianni Ekaterini, Anastasios Ioannidis, Efstathios Chronopoulos, Stylianos Chatzipanagiotou","doi":"10.33393/jcb.2025.3486","DOIUrl":"10.33393/jcb.2025.3486","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a life-threatening condition and a major cause of hospital mortality worldwide. This study investigated the diagnostic utility of monocyte mean volume (MONO MEAN-V), monocyte distribution width (MDW), monocyte mean conductivity (MONO MEAN-C), and monocyte standard deviation conductivity (MONO Sd-C) for sepsis, compared to conventional markers.</p><p><strong>Methods: </strong>A prospective cohort study was conducted in two centers, enrolling adult patients classified into three groups: sepsis, septic shock, and febrile. Blood was drawn from septic patients on days 1, 3, and 5 of admission. MDW and other inflammatory parameters were measured in all patients.</p><p><strong>Results: </strong>Patients with sepsis or septic shock exhibited significantly elevated MONO MEAN-V, MDW, and MONO MEAN-C and lower MONO Sd-C compared to febrile patients. Among the biomarkers evaluated, MDW emerged as a reliable predictor of sepsis. A cut-off MDW value of 25.1 on day 1 demonstrated optimal diagnostic performance, with an area under the ROC curve of 0.84 (95% CI: 0.77-0.91), sensitivity of 75%, and specificity of 91.2%.</p><p><strong>Conclusions: </strong>MDW appears to be a cost-effective, rapid marker for sepsis detection, performing at least as effectively as existing biomarkers. Our findings corroborate other published studies, highlighting MDW's potential to enhance early sepsis recognition.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"21-29"},"PeriodicalIF":0.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144972819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-28eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3175
Inga Claus, Meike Hoffmeister, Constantin Remus, Werner Dammermann, Ourania Gioti, Oliver Ritter, Daniel Patschan, Susann Patschan
Background: Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantly increases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial in these patients, but it may be underestimated using the current criteria, as they do not include nontraditional CVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarker for cardiovascular and rheumatic diseases. In this study, we examined the role of sST-2 in assessing CVR in RA.
Methods: Monocentric, retrospective, observational trial. Inclusion of RA patients on variable DMARD therapy. Analysis of RA disease using established scores (DAS 28, VAS, HFQ), clinical findings (number of swollen and painful joints), and laboratory investigation. Documentation of numerous CVR variables. Quantification of soluble sST-2 by ELISA.
Results: In total, 129 individuals were included. Soluble sST-2 did neither correlate nor was associated with any variable of RA disease activity. In contrast, significant associations were identified between sST-2 and a number of established CVR markers.
Conclusions: The data indicates a novel role for sST-2 in CVR prediction in RA.
{"title":"Soluble interleukin-33 receptor (sST-2): a novel marker for assessing cardiovascular risk in rheumatoid arthritis.","authors":"Inga Claus, Meike Hoffmeister, Constantin Remus, Werner Dammermann, Ourania Gioti, Oliver Ritter, Daniel Patschan, Susann Patschan","doi":"10.33393/jcb.2025.3175","DOIUrl":"10.33393/jcb.2025.3175","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is the most common inflammatory rheumatic disease, and it significantly increases the risk of cardiovascular disease and death. The evaluation of cardiovascular risk (CVR) is crucial in these patients, but it may be underestimated using the current criteria, as they do not include nontraditional CVR factors. Soluble ST-2, which is the circulating form of the IL-33 receptor, has been identified as a biomarker for cardiovascular and rheumatic diseases. In this study, we examined the role of sST-2 in assessing CVR in RA.</p><p><strong>Methods: </strong>Monocentric, retrospective, observational trial. Inclusion of RA patients on variable DMARD therapy. Analysis of RA disease using established scores (DAS 28, VAS, HFQ), clinical findings (number of swollen and painful joints), and laboratory investigation. Documentation of numerous CVR variables. Quantification of soluble sST-2 by ELISA.</p><p><strong>Results: </strong>In total, 129 individuals were included. Soluble sST-2 did neither correlate nor was associated with any variable of RA disease activity. In contrast, significant associations were identified between sST-2 and a number of established CVR markers.</p><p><strong>Conclusions: </strong>The data indicates a novel role for sST-2 in CVR prediction in RA.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"5-11"},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-28eCollection Date: 2025-01-01DOI: 10.33393/jcb.2025.3510
Ola Magne Vagnildhaug, Ragnhild H Habberstad, Øyvind Salvesen, Trude R Balstad, Asta Bye, Olav Dajani, Stein Kaasa, Pål Klepstad, Tora S Solheim
Background: Systemic inflammation is crucial in cancer cachexia, but the optimal measurement method remains unclear. This study compares markers of systemic inflammation (MoSI) in predicting weight loss in patients with metastatic cancer.
Methods: This prospective, observational multi-center study involved patients undergoing radiotherapy for bone metastases. Baseline assessments included demographics, clinical characteristics, previous weight loss, and appetite loss. MoSI included: C-reactive protein (CRP), albumin, white blood cells, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, interleukin-6 (IL-6), modified Glasgow Prognostic Score (mGPS), and Prognostic Nutritional Index. Body weight was recorded at baseline, 3, and 8 weeks post-radiotherapy. Multiple linear regression assessed MoSI's predictive ability for weight loss, adjusting for previous weight loss, appetite loss, and primary tumour type. Goodness-of-fit was assessed using adjusted R2.
Results: Out of 574 recruited patients, 540 and 470 were analyzed at 3 and 8 weeks, respectively. The median age (IQR) was 67 (15), 330 (61%) were male, and 397 (74%) had a Karnofsky performance status ≥70. In a base model without MoSI, significant predictors of weight loss at 3 weeks were appetite loss and urological, lung, and gastrointestinal cancer (adjusted R2 of 0.064), while at 8 weeks, urological and lung cancer were significant (adjusted R2 of 0.035). At 3 weeks, all MoSI significantly improved the base model, with adjusted R2 between 0.078 and 0.091. At 8 weeks: CRP, mGPS, albumin and IL-6 improved the model; however only CRP and mGPS retained an adjusted R2 of ~0.09.
Conclusions: All MoSI predicted weight loss, but CRP and mGPS were the most optimal.
{"title":"A comparison of inflammatory markers' potential to predict weight loss in advanced cancer: a prospective observational study.","authors":"Ola Magne Vagnildhaug, Ragnhild H Habberstad, Øyvind Salvesen, Trude R Balstad, Asta Bye, Olav Dajani, Stein Kaasa, Pål Klepstad, Tora S Solheim","doi":"10.33393/jcb.2025.3510","DOIUrl":"10.33393/jcb.2025.3510","url":null,"abstract":"<p><strong>Background: </strong>Systemic inflammation is crucial in cancer cachexia, but the optimal measurement method remains unclear. This study compares markers of systemic inflammation (MoSI) in predicting weight loss in patients with metastatic cancer.</p><p><strong>Methods: </strong>This prospective, observational multi-center study involved patients undergoing radiotherapy for bone metastases. Baseline assessments included demographics, clinical characteristics, previous weight loss, and appetite loss. MoSI included: C-reactive protein (CRP), albumin, white blood cells, neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, interleukin-6 (IL-6), modified Glasgow Prognostic Score (mGPS), and Prognostic Nutritional Index. Body weight was recorded at baseline, 3, and 8 weeks post-radiotherapy. Multiple linear regression assessed MoSI's predictive ability for weight loss, adjusting for previous weight loss, appetite loss, and primary tumour type. Goodness-of-fit was assessed using adjusted R<sup>2</sup>.</p><p><strong>Results: </strong>Out of 574 recruited patients, 540 and 470 were analyzed at 3 and 8 weeks, respectively. The median age (IQR) was 67 (15), 330 (61%) were male, and 397 (74%) had a Karnofsky performance status ≥70. In a base model without MoSI, significant predictors of weight loss at 3 weeks were appetite loss and urological, lung, and gastrointestinal cancer (adjusted R<sup>2</sup> of 0.064), while at 8 weeks, urological and lung cancer were significant (adjusted R<sup>2</sup> of 0.035). At 3 weeks, all MoSI significantly improved the base model, with adjusted R<sup>2</sup> between 0.078 and 0.091. At 8 weeks: CRP, mGPS, albumin and IL-6 improved the model; however only CRP and mGPS retained an adjusted R<sup>2</sup> of ~0.09.</p><p><strong>Conclusions: </strong>All MoSI predicted weight loss, but CRP and mGPS were the most optimal.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"12-20"},"PeriodicalIF":0.0,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: This research was performed to evaluate Irisin and Insulin concentrations in Thyroid patients.
Material and methods: This investigation was performed as a cross-sectional study within the Biochemistry Department at KMC, Mangalore, and the Central Lab at KMCH-AT, Mangalore. Participants were classified into two cohorts: those having regular thyroid function as well as those having thyroid disorder, including both hypothyroid and hyperthyroid patients, with 28 individuals (n = 28) in each category based on thyroid stimulating hormone (TSH) levels obtained during thyroid dysfunction screenings. Socio-demographic variables like height, weight, and body mass index were calculated, along with the assessment of hypertensive or hypotensive conditions. Insulin levels were quantified using an automated analyzer system. Statistical analyses were performed utilizing Easy-R (EZR) version 1.55, developed by Jichi Medical University in Saitama, Japan. The normal distribution of the parameters was evaluated through normality tests, with t-tests and Kruskal-Wallis tests applied as appropriate.
Results: Irisin levels significantly declined in hypothyroid individuals while showing an insignificant rise in hyperthyroidism. Insulin levels significantly increased in hyperthyroid patients compared to normal and hypothyroid groups. A positive correlation between insulin and irisin was found in hypothyroidism, while a negative correlation was observed in hyperthyroidism.
Conclusion: Preliminary findings of this study indicate a potential interdependence between Irisin and thyroid levels. Investigating the interaction between the thyroid profile and irisin can pave the way for considering irisin as a biomarker for novel treatment strategies in thyroid disorders and metabolic conditions.
{"title":"Irisin and Insulin Interplay in Thyroid Disorders: A Pilot Study.","authors":"Amisha Malhotra, Gayathri M Rao, Aradhana Marathe, Sowmya Ananda Jothi, Vinod Chandran","doi":"10.33393/jcb.2025.3396","DOIUrl":"10.33393/jcb.2025.3396","url":null,"abstract":"<p><strong>Background: </strong>This research was performed to evaluate Irisin and Insulin concentrations in Thyroid patients.</p><p><strong>Material and methods: </strong>This investigation was performed as a cross-sectional study within the Biochemistry Department at KMC, Mangalore, and the Central Lab at KMCH-AT, Mangalore. Participants were classified into two cohorts: those having regular thyroid function as well as those having thyroid disorder, including both hypothyroid and hyperthyroid patients, with 28 individuals (n = 28) in each category based on thyroid stimulating hormone (TSH) levels obtained during thyroid dysfunction screenings. Socio-demographic variables like height, weight, and body mass index were calculated, along with the assessment of hypertensive or hypotensive conditions. Insulin levels were quantified using an automated analyzer system. Statistical analyses were performed utilizing Easy-R (EZR) version 1.55, developed by Jichi Medical University in Saitama, Japan. The normal distribution of the parameters was evaluated through normality tests, with t-tests and Kruskal-Wallis tests applied as appropriate.</p><p><strong>Results: </strong>Irisin levels significantly declined in hypothyroid individuals while showing an insignificant rise in hyperthyroidism. Insulin levels significantly increased in hyperthyroid patients compared to normal and hypothyroid groups. A positive correlation between insulin and irisin was found in hypothyroidism, while a negative correlation was observed in hyperthyroidism.</p><p><strong>Conclusion: </strong>Preliminary findings of this study indicate a potential interdependence between Irisin and thyroid levels. Investigating the interaction between the thyroid profile and irisin can pave the way for considering irisin as a biomarker for novel treatment strategies in thyroid disorders and metabolic conditions.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"14 ","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16eCollection Date: 2024-01-01DOI: 10.33393/jcb.2024.3146
Dalia Ahmed, Ebtesam A Abdel-Shafy, Elsadig Ahmed Adam Mohammed, Husam Elden Alnour Bakhet Alnour, Amar Mohamed Ismail, Stefano Cacciatore, Luiz Fernando Zerbini
Introduction: Prostate cancer (PCa) management presents a multifaceted clinical challenge, intricately linking oncological considerations with cardiovascular health. Despite the recognized importance of lipid metabolism and hypertension in this interwoven relationship, their involvement in PCa development remains partially understood. This study aimed to explore variations in plasma metabolome among Sudanese PCa patients and their associated comorbidities.
Methods: Plasma samples were collected from 50 patients across four hospitals in Sudan and profiled by nuclear magnetic resonance (NMR) spectroscopy. One-dimensional proton NMR spectra were acquired for each sample using standard nuclear Overhauser effect spectroscopy pulse sequence presat on a 500 MHz Bruker Avance III HD NMR spectrometer. Metabolite concentrations were quantified using R scripts developed in-house. Univariate and multivariate analyses were generated in the R software.
Results: Patients were categorized into four distinct metabotypes based on their metabolic profiles, and statistical analyses were conducted to evaluate the significance of observed differences. Our findings revealed high levels of fatty acids, phospholipids, cholesterol, valine, leucine, and isoleucine associated with non-hypertensive patients. In contrast, hypertensive patients were associated with high GlycA and GlycB levels and altered amino acid metabolism.
Conclusion: These findings underscore the intricate interplay between metabolic dysregulation and hypertension in PCa patients. Further research is warranted to elucidate the precise molecular pathways underlying lipid metabolism in PCa and to explore the therapeutic potential of targeting these pathways. In conclusion, our study contributes to a deeper understanding of the metabolic landscape of PCa in Sudanese patients, emphasizing the importance of personalized approaches in cancer management.
简介:前列腺癌(PCa)的管理提出了一个多方面的临床挑战,错综复杂地将肿瘤学考虑与心血管健康联系起来。尽管脂质代谢和高血压在这种相互交织的关系中具有公认的重要性,但它们在PCa发展中的作用仍然部分被理解。本研究旨在探讨苏丹PCa患者血浆代谢组的变化及其相关的合并症。方法:从苏丹四家医院的50名患者中收集血浆样本,并通过核磁共振(NMR)波谱分析。在500 MHz Bruker Avance III HD核磁共振波谱仪上,使用标准核奥豪瑟效应脉冲序列获得每个样品的一维质子核磁共振波谱。使用内部开发的R脚本对代谢物浓度进行量化。在R软件中生成单变量和多变量分析。结果:根据代谢谱将患者分为四种不同的代谢型,并进行统计学分析,评价观察到的差异的意义。我们的研究结果显示,高水平的脂肪酸、磷脂、胆固醇、缬氨酸、亮氨酸和异亮氨酸与非高血压患者有关。相反,高血压患者与高GlycA和GlycB水平和氨基酸代谢改变有关。结论:这些发现强调了前列腺癌患者代谢失调与高血压之间复杂的相互作用。需要进一步的研究来阐明前列腺癌中脂质代谢的确切分子途径,并探索针对这些途径的治疗潜力。总之,我们的研究有助于更深入地了解苏丹前列腺癌患者的代谢情况,强调个性化方法在癌症管理中的重要性。
{"title":"Altered amino and fatty acids metabolism in Sudanese prostate cancer patients: insights from metabolic analysis.","authors":"Dalia Ahmed, Ebtesam A Abdel-Shafy, Elsadig Ahmed Adam Mohammed, Husam Elden Alnour Bakhet Alnour, Amar Mohamed Ismail, Stefano Cacciatore, Luiz Fernando Zerbini","doi":"10.33393/jcb.2024.3146","DOIUrl":"10.33393/jcb.2024.3146","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer (PCa) management presents a multifaceted clinical challenge, intricately linking oncological considerations with cardiovascular health. Despite the recognized importance of lipid metabolism and hypertension in this interwoven relationship, their involvement in PCa development remains partially understood. This study aimed to explore variations in plasma metabolome among Sudanese PCa patients and their associated comorbidities.</p><p><strong>Methods: </strong>Plasma samples were collected from 50 patients across four hospitals in Sudan and profiled by nuclear magnetic resonance (NMR) spectroscopy. One-dimensional proton NMR spectra were acquired for each sample using standard nuclear Overhauser effect spectroscopy pulse sequence presat on a 500 MHz Bruker Avance III HD NMR spectrometer. Metabolite concentrations were quantified using R scripts developed in-house. Univariate and multivariate analyses were generated in the R software.</p><p><strong>Results: </strong>Patients were categorized into four distinct metabotypes based on their metabolic profiles, and statistical analyses were conducted to evaluate the significance of observed differences. Our findings revealed high levels of fatty acids, phospholipids, cholesterol, valine, leucine, and isoleucine associated with non-hypertensive patients. In contrast, hypertensive patients were associated with high GlycA and GlycB levels and altered amino acid metabolism.</p><p><strong>Conclusion: </strong>These findings underscore the intricate interplay between metabolic dysregulation and hypertension in PCa patients. Further research is warranted to elucidate the precise molecular pathways underlying lipid metabolism in PCa and to explore the therapeutic potential of targeting these pathways. In conclusion, our study contributes to a deeper understanding of the metabolic landscape of PCa in Sudanese patients, emphasizing the importance of personalized approaches in cancer management.</p>","PeriodicalId":37524,"journal":{"name":"Journal of Circulating Biomarkers","volume":"13 ","pages":"36-44"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142855367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}